Elevance reports results July 15, followed by UnitedHealth July 16, and CVS Health on Aug. 5.
LATEST ARTICLES
Alignment Healthcare shares rose Thursday, with one analyst saying a selloff after a whistleblower lawsuit was “overdone.”
Peptides are drugs that promote everything from athletic performance to skin care, mental focus and romance. The drug agency has a hearing in late July that might touch off a boom. Here’s what you need to know about what they are and whether to invest in them.
Medicare is launching a temporary program that will cover Novo’s Wegovy injection and tablets, as well as Lilly’s Zepbound KwikPen formulation and its Foundayo tablets.
XBI has “moved higher a record 12 of 13 months,” Mizuho healthcare sector specialist Jared Holz wrote Friday.
Florida’s attorney general says he is examining whether CVS’s pharmacy benefit manager steers patients to its own pharmacies.
The healthcare giant is trying to come back from a plummet in its share price last year.
Hims & Hers has made clear its interest in the peptides. It owns a peptide manufacturer and said it “sees meaningful potential” in the drugs.
Barclays upgraded its rating of Oscar to overweight, a buy equivalent, and reiterated its overweight rating on Centene in a new research note.
The president’s financial disclosures reveal several trades in UnitedHealth and other insurers as the government set Medicare rate policies.
President Donald Trump said Marty Makary was “having some difficulty” in the role of FDA commissioner.
Eli Lilly faces challenges in the GLP-1 market, with Novo Nordisk gaining a timing advantage in both injectable and oral drug approvals.
Evercore ISI analysts cautioned investors, writing Thursday that “with regards to current headlines, we see no meaningful revenue opportunity.”
CVS Health’s Aetna was the third-largest provider of Medicare Advantage plans in 2025, behind UnitedHealth Group and Humana.
The insurance company has plans to get smaller in Medicare Advantage. Goldman Sachs likes the idea.
The company modestly raised its forecast for 2026 profits amid a shift in its drug pricing and CEO transition.
The stock has slumped this year, seesawing on news of how much the government plans to pay insurers that operate Medicare Advantage health plans for seniors.
Regeneron, in a press release, said it would get tariff relief for three years under terms with the U.S. Department of Commerce.
The health insurer cites improvements in Medicare Advantage and says it’s making $1.5 billion in AI investments.
The health secretary told lawmakers the department’s proposed budget focuses on prevention because it has better outcomes than treatment.
of 4 pages